These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21047223)

  • 1. Safety of recombinant activated factor VII in randomized clinical trials.
    Levi M; Levy JH; Andersen HF; Truloff D
    N Engl J Med; 2010 Nov; 363(19):1791-800. PubMed ID: 21047223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label use of recombinant activated factor VII--safe or not safe?
    Aledort LM
    N Engl J Med; 2010 Nov; 363(19):1853-4. PubMed ID: 21047230
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.
    Diringer MN; Skolnick BE; Mayer SA; Steiner T; Davis SM; Brun NC; Broderick JP
    Stroke; 2008 Mar; 39(3):850-6. PubMed ID: 18239180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of recombinant activated factor VII in randomized clinical trials.
    Yank V; Stafford RS
    N Engl J Med; 2011 Feb; 364(6):575; author reply 575-6. PubMed ID: 21306248
    [No Abstract]   [Full Text] [Related]  

  • 5. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
    MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
    Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Judicious Use of Recombinant Factor VIIa.
    Goodnough LT; Levy JH
    Semin Thromb Hemost; 2016 Mar; 42(2):125-32. PubMed ID: 26838698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.
    Guzzetta NA; Russell IA; Williams GD
    Anesth Analg; 2012 Aug; 115(2):364-78. PubMed ID: 22652310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials.
    Johansson PI
    Vox Sang; 2008 Jul; 95(1):1-7. PubMed ID: 18435677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Stanworth SJ; Birchall J; Doree CJ; Hyde C
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005011. PubMed ID: 17443565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
    Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
    Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of recombinant activated factor VII in randomized clinical trials.
    Patel A; Cooper N; Laffan MA
    N Engl J Med; 2011 Feb; 364(6):574; author reply 575-6. PubMed ID: 21306250
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Simpson E; Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
    Cochrane Database Syst Rev; 2012 Mar; (3):CD005011. PubMed ID: 22419303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials.
    Hsia CC; Chin-Yee IH; McAlister VC
    Ann Surg; 2008 Jul; 248(1):61-8. PubMed ID: 18580208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
    Gill R; Herbertson M; Vuylsteke A; Olsen PS; von Heymann C; Mythen M; Sellke F; Booth F; Schmidt TA
    Circulation; 2009 Jul; 120(1):21-7. PubMed ID: 19546387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven
    Marsh K; Green D; Raco V; Papadopoulos J; Ahuja T
    Ther Adv Cardiovasc Dis; 2020; 14():1753944720924255. PubMed ID: 32449469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged prothrombin time after recombinant activated factor VII therapy in critically bleeding trauma patients is associated with adverse outcomes.
    McMullin NR; Wade CE; Holcomb JB; Nielsen TG; Rossaint R; Riou B; Rizoli SB; Kluger Y; Choong PI; Warren B; Tortella BJ; Boffard KD;
    J Trauma; 2010 Jul; 69(1):60-9. PubMed ID: 20622579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
    Brophy GM; Candeloro CL; Robles JR; Brophy DF
    Ann Pharmacother; 2013 Apr; 47(4):447-54. PubMed ID: 23535812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
    Cochrane Database Syst Rev; 2011 Feb; (2):CD005011. PubMed ID: 21328270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.